ADMA Biologics Inc. (NASDAQ: ADMA)’s stock price has dropped by -2.23 in relation to previous closing price of 4.03. Nevertheless, the company has seen a loss of -2.48% in its stock price over the last five trading days.
Is It Worth Investing in ADMA Biologics Inc. (NASDAQ: ADMA) Right Now?
Moreover, the 36-month beta value for ADMA is 0.88.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
The public float for ADMA is 176.84M and currently, short sellers hold a 6.31% of that float. On May 26, 2023, ADMA’s average trading volume was 2.43M shares.
ADMA’s Market Performance
The stock of ADMA Biologics Inc. (ADMA) has seen a -2.48% decrease in the past week, with a 19.39% rise in the past month, and a 15.20% gain in the past quarter. The volatility ratio for the week is 2.94%, and the volatility levels for the past 30 days are at 4.15% for ADMA. The simple moving average for the last 20 days is 4.76% for ADMA’s stock, with a simple moving average of 23.64% for the last 200 days.
ADMA Trading at 13.98% from the 50-Day Moving Average
After a stumble in the market that brought ADMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.37% of loss for the given period.
Volatility was left at 4.15%, however, over the last 30 days, the volatility rate increased by 2.94%, as shares surge +19.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +25.88% upper at present.
During the last 5 trading sessions, ADMA fell by -2.48%, which changed the moving average for the period of 200-days by +94.09% in comparison to the 20-day moving average, which settled at $3.79. In addition, ADMA Biologics Inc. saw 1.55% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at ADMA starting from Grossman Adam S, who purchase 14,983 shares at the price of $2.86 back on Dec 09. After this action, Grossman Adam S now owns 2,203,708 shares of ADMA Biologics Inc., valued at $42,851 using the latest closing price.
Grossman Adam S, the President and CEO of ADMA Biologics Inc., purchase 14,982 shares at $2.86 during a trade that took place back on Dec 09, which means that Grossman Adam S is holding 1,143,426 shares at $42,849 based on the most recent closing price.
Stock Fundamentals for ADMA
Current profitability levels for the company are sitting at:
- -25.69 for the present operating margin
- +22.42 for the gross margin
The net margin for ADMA Biologics Inc. stands at -42.77. Equity return is now at value -37.20, with -14.80 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 6.89.
To wrap up, the performance of ADMA Biologics Inc. (ADMA) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.